Advances in the Study of Bioactive Nanoparticles for the Treatment of HCC and Its Postoperative Residual Cancer.

Abstract

Primary hepatocellular carcinoma (HCC, hepatocellular carcinoma) is the third leading cause of tumor death in the world and the second leading cause in China. The high recurrence rate at 5 years after surgery also seriously affects the long-term survival of HCC patients. For reasons such as poor liver function, large tumors, or vascular invasion, only relatively limited palliative treatment is available. Therefore, effective diagnostic and therapeutic strategies are needed to improve the complex microenvironment and block the mechanism of tumor development in order to treat the tumor and prevent recurrence. A variety of bioactive nanoparticles have been shown to have therapeutic effects on hepatocellular carcinoma and have the advantages of improving drug solubility, reducing drug side effects, preventing degradation in the blood, increasing drug exposure time, and reducing drug resistance. The development of bioactive nanoparticles is expected to complete the current clinical therapeutic approach. In this review, we discuss the therapeutic advances of different nanoparticles for hepatocellular carcinoma and discuss their potential for postoperative applications with respect to possible mechanisms of hepatocellular carcinoma recurrence. We further discuss the limitations regarding the application of NPs and the safety of NPs.

• Authors: Yanxu Li, Hao Zou, Zekun Zheng, Zhuoheng Liu, Huiyuan Hu, Wei Wu, Tao Wang
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 18 Pg. 2721-2735 ( 2023) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 37250475 (Publication Type: Journal Article, Review)
• Copyright: © 2023 Li et al.

Topics

• Humans
• Carcinoma, Hepatocellular (pathology)
• Liver Neoplasms (pathology)
• Neoplasm, Residual
• Nanoparticles
• China
• Tumor Microenvironment